Neuroinflammation in Parkinson's disease and its potential as therapeutic target
about
Prothrombin Kringle-2: A Potential Inflammatory Pathogen in the Parkinsonian Dopaminergic SystemPutative Role of Red Wine Polyphenols against Brain Pathology in Alzheimer's and Parkinson's DiseaseMitochondrial dysfunction in Parkinson's diseasePathophysiological Role of Neuroinflammation in Neurodegenerative Diseases and Psychiatric DisordersStriatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's DiseaseCopy number variability in Parkinson's disease: assembling the puzzle through a systems biology approachExendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines.Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate.Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T MutantParkinson's disease-associated genetic variation is linked to quantitative expression of inflammatory genes.e-Cadherin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Parkinson Disease.CD200 Inhibits Inflammatory Response by Promoting KATP Channel Opening in Microglia Cells in Parkinson's Disease.Microglia P2Y6 receptor is related to Parkinson's disease through neuroinflammatory processParkinson's disease is associated with DNA methylation levels in human blood and saliva.Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease.Changing paradigm to target microglia in neurodegenerative diseases: from anti-inflammatory strategy to active immunomodulation.Economic Burden Analysis of Parkinson's Disease Patients in ChinaThe implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.Overexpression of α-synuclein in an astrocyte cell line promotes autophagy inhibition and apoptosis.Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular unitsStructure, function and disease relevance of Omega-class glutathione transferases.Glial Na(+) -dependent ion transporters in pathophysiological conditions.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Relationship Between Obesity, Alzheimer's Disease, and Parkinson's Disease: an Astrocentric View.Targeted inhibition of RAGE in substantia nigra of rats blocks 6-OHDA-induced dopaminergic denervationCardiolipin in Central Nervous System Physiology and Pathology.Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments.Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death.Astroglia as a cellular target for neuroprotection and treatment of neuro-psychiatric disorders.Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegenerationDopaminergic Regulation of Innate Immunity: a Review.The Role of Microglia in Retinal Neurodegeneration: Alzheimer's Disease, Parkinson, and Glaucoma.Contribution of Pro-inflammatory Cytokine Signaling within Midbrain Periaqueductal Gray to Pain Sensitivity in Parkinson's Disease via GABAergic Pathway.Rice bran derivatives alleviate microglia activation: possible involvement of MAPK pathway.Common gene-network signature of different neurological disorders and their potential implications to neuroAIDS.Neuroprotective potential of Quercetin in combination with piperine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.Dynamic Changes in the Nigrostriatal Pathway in the MPTP Mouse Model of Parkinson's DiseaseProximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration
P2860
Q26738336-D9C5DB1D-76FA-4709-B403-C41AC5EB4C67Q26738450-1C753B9C-AFA0-4FB5-97FD-C85D40375760Q26741872-B923BAD5-1803-4554-93B3-12B2FA6482C8Q26745690-49EF6987-C19F-4A53-9D18-6665E748ACF8Q26768220-689BB553-065F-44F5-9EBB-FEE3E7EC6440Q28277871-B800665D-D3B5-4B23-B442-00C339A6FE0BQ33364337-E63BDBB9-6C4B-4293-86DC-C8654AB1894AQ33708923-B55DB051-CFB5-4E49-8E9B-3D154126955EQ33835745-7E2AFC3D-B32F-4044-8AC6-319DC6D8ECBCQ36131340-CACDC33B-1D3E-4902-A11D-0FB5862B2B72Q36346103-2F8F0CD7-37DA-4483-87F7-9CE135070A32Q36856915-52492D4D-8F4E-4C54-9114-62102419B165Q37029415-C96210B2-F46C-4AFB-921C-6D232E9D5651Q37655232-6CBE15FE-8E31-4026-9CFD-0C95038F7FB9Q38603331-A2C44B5D-FD82-43DF-86F4-CD7849618AC8Q38617000-CF6231D0-4A03-4B26-92AD-C796238D721DQ38623708-1B676C97-D719-4879-9B34-A3D8D4382DEFQ38633556-D6577192-CE75-4971-946C-CBA0E85858BDQ38659681-3D9CD827-FF3B-4569-8A55-88ADCEA1BC0DQ38670012-2C4AE872-ACEE-424F-B807-1E692D12A0F9Q38701541-F600E47A-B5FF-4907-A50E-F28B18BC3FA2Q38751291-7C5293BB-12F0-4003-87CE-14FC6698C3B5Q38780816-9D8DB08C-4A98-4C1A-ACB6-CE669A31A2DEQ38908720-4D107C55-3073-4DC1-A950-FE3F996ED923Q38951947-6098D4C8-64CA-47B5-8AC2-E9E62C97209FQ38994712-75A2671B-2FBA-464B-AFE0-347F447A7786Q39018573-D35BA564-9AAB-4CDA-8032-C7523954F3F8Q39063404-A58A49D0-7A69-41D7-9713-0270DE46F5A3Q39148230-A6C96BA6-39C2-40D6-ADFB-B13B1627F328Q39151414-7E5531BC-1608-4F0D-9AF1-5842C1E1330CQ39181656-04240064-96CA-4A61-B7DE-C9443A1E01ABQ39327711-DC2D2DD1-6AD2-418F-8760-7BF2A4693CE9Q39348712-B841F9E5-11EC-4A23-84B8-0567F41C654FQ39449147-3478F567-47DB-48FC-9540-9CAC2573DF9FQ39509256-E34836DA-DAC8-4333-A676-14600042CFCFQ39683786-83573349-20C6-4218-B30A-1502D2DBA2EDQ40089319-7D52F05E-84C5-47C9-B2D9-B1E05ABC3292Q40500475-C956CD62-1C3A-49B4-89EB-971B56C02F73Q41376219-F420A5EB-E85B-4C78-9BA6-41DA21EB7FDEQ41613567-08C62EEC-B0E4-4E0A-8A44-D29DA5BBF039
P2860
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@ast
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@en
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@nl
type
label
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@ast
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@en
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@nl
altLabel
Neuroinflammation in Parkinson’s disease and its potential as therapeutic target
@en
prefLabel
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@ast
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@en
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@nl
P2860
P921
P3181
P1476
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
@en
P2093
Qinqin Wang
P2860
P2888
P356
10.1186/S40035-015-0042-0
P407
P577
2015-10-12T00:00:00Z
P5875
P6179
1050492278